Animal studies
showed promising
effect: the
report
•
A short
pre-clinical
human study
study showed a
promise
(shall be given
upon request)
•
Phase-1 study
may begin in
2009-2010.
About Stroke -
A Flash Presentation
The Succession
of New
Generation
Preventive
Therapies of JNI
Medical
Corporation
Efficacy of Vaccine
against Stroke
Stroke Vaccine Shows
Promise in our Animal
and in pre-clinical
human studies:
Strokes occur in one of
two ways; a blood clot
forms and then cuts off
circulation to part of
the brain or a blood
vessel ruptures and
leaks blood into the
brain. In both cases, a
stroke can lead to
permanent disability or
death.
JN-Medical Corporation
has developed a vaccine
against Stroke. While
the repeated animal
studies suggest the
vaccine works in pigs
and their anatomy is
closer to human. Strokes
begin when inflammation
occurs on a molecular
level in blood vessels
as part of a response by
the immune system.
During a 5 year long
study, the pigs that
received treatment
with the vaccine had
fewer strokes caused by
blood clots than those
that received Placebo.
None of the pigs that
had treatment suffered
from a hemorrhagic
stroke, in which blood
vessels rupture. A
short human study showed
promising preventive and
therapeutic effect.
Full scale Phase-1 study
is proposed to be
conducted at Clinical
Trial Center, Iowa State
University in 2009-2010.
The vaccine could offer
a "new dimension" in
stroke prevention. The
vaccine would most
likely be targeted to
people who are
susceptible to strokes.
Impact of
Stroke:
Stroke is the third
leading killer in the
United States, resulting
in the following
statistics annually:
•750,000+ victims;
•160,000 deaths (3rd
leading cause of death);
•266,000 survivors with
permanent disabilities;
•30,000 new permanent
admissions to nursing
homes; •Over 4
million living survivors
of stroke; •Every
45 seconds in the USA,
someone has a stroke;
•Huge economic impact
with costs of $40-$70
billion per year.
Vaccine against
Hepatitis C, Genital
Herpes and Tuberculosis
are at pre-clinical
stage.
